ChemicalBook >   Product Catalog >  API >  Antibiotics >  Aminoglycosides drugs

Aminoglycosides drugs

More
Less

Aminoglycoside mainly takes effect on the bacterial ribosome in vivo, inhibiting bacterial protein synthesis as well as undermining the integrity of the bacterial cell membrane. Aminoglycoside, through relying on the energy dependent transport system of Ⅱ in vivo, participates into binding to the 30S ribosomal subunit, causing insertion of erroneous proteins into the cell membrane, resulting in the changes in the cell membrane permeability as well as the leakage of intracellular potassium, adenine nucleoside as well as important substances, further resulting in rapid bacterial cell death. The entering of large amount of aminoglycoside molecule into the bacterial cell is an aerobic energy-consuming process. This process will be inhibits under hypoxic conditions. In present time, the clinical applied aminoglycosides all can effectively inhibit the prokaryotic protein synthesis upon reaching the therapeutic concentrations (≤25 μg/ml). Aminoglycosides have strong bactericidal effect against bacteria in stationary phase, being an stationary-phase bactericidal agents.

1. Antibacterial spectrum and drugs resistance; aminoglycoside has strong antibacterial effect against aerobic gram-negative bacteria such as Escherichia coli, Klebsiella, Enterobacter, Proteus, Shigella, Serratia spp., Salmonella spp. However, its antibacterial effect against Alcaligenes, Moraxella, Citrobacter, Acinetobacter, Brucella, meningococcus and other gram-negative bacteria is poor. It also has poor effect against each group of streptococci (such as group-A streptococci, Streptococcus viridans, and Streptococcus pneumoniae). The majority of Enterococcus is resistant to it. Mycobacterium tuberculosis is sensitive to streptomycin. Aminoglycoside has stronger antibacterial effect in an alkaline environment with Ca2 +, Mg2 +, Na +, NH4 +, K + and other cations being capable of inhibiting the antibacterial activity.

2. The in vivo distribution of aminoglycosides; aminoglycoside has poor absorption upon oral administration; only through intestinal infections can it be distributed to a number of vital organs in the body such as penetrating into the pleural or peritoneal effusions. This class of drugs is primarily subject to renal excretion with relatively high urine concentrations, thus being conducive to the treatment of urinary tract infection. However, they have lower concentration in the bile with poor efficacy in treating the biliary tract infections. They are not easy to penetrate through the blood - brain barrier, and thus not suitable to the central infection.

3. Indications; at present time, aminoglycosides are still commonly used drugs in the domestic clinical practice. It is mainly used for the treatment of severe systemic infections caused by aerobic gram-negative bacilli including biliary tract infections, bone and joint infections, pneumonia, sepsis, urinary tract infection, skin and soft tissue infections. However, in case of treatment of serious infection or sepsis caused unknown pathogens, or severe Gram-negative bacilli sepsis, pneumonia, meningitis, or Staphylococcus aureus or Enterococcus infection, this class of drugs is often combined with other antibiotics. Aminoglycoside has a poor antibacterial effect against Streptococcus while the streptococcus is one of the major strains that caused the upper respiratory tract infection. Therefore, in this case, application of this class of drugs is unreasonable, and can not only delay treatment, but also increase the incidence of adverse reactions.
Medication methods; in case of dealing with serious infections, regardless of whether the patients have normal renal function or not, they should be subject to the first-time impulse amount in order to ensure the achievement of effective concentration in the tissues. The applied dose should be calculated according to the weight with fat subtracted (or standard weight) + 40% × overweight part, since different patients often have greatly varied plasma concentration and half-life, the blood concentration should be monitored in conditions allowed to adjust the dose so that individualized dosing can be achieved.

4. The principle of combination therapy; aminoglycoside, when used in combination with penicillins or cephalosporin, can often lead to synergies effects. The combinations of penicillin and streptomycin have synergistic effect against Streptococcus viridans. Other possible combinations with potential synergistic effect include: the combination with enzyme-resistant semi-synthetic penicillin (such as oxacillin) for treatment of Staphylococcus aureus; the combination with penicillin (or ampicillin) or vancomycin for treatment of Enterococcus; the combination with cephalosporin for the treatment of Klebsiella pneumoniae; the combination with penicillin or ampicillin for the treatment of Listeria; the combination with piperacillin and carbenicillin for the treatment of Pseudomonas aeruginosa.

Precautions
1. Aminoglycosides have cross-allergy with each other with allergic patients disabled.
2. Combination with penicillin G can have synergistic antibacterial effect against almost all kinds of Streptococcus faecalis and its variants such as Streptococcus faecium species and Streptococcus durans. Combination with enough amount of carbenicillin has synergistic antibacterial effect against some sensitive strains of Pseudomonas aeruginosa.
3. Combination with alkaline drugs (such as sodium bicarbonate, aminophylline, etc.) can enhance the antibacterial effectiveness but can also lead to a corresponding increase in the toxicity; combination with strong diuretics (such as furosemide, ethacrynic acid, etc.) can increase the renal toxicity; combination with other ototoxic drugs (such as erythromycin, etc.) can increase the ototoxicity; combination with cephalosporins can increase the renal toxicity.

Click on the specific product, view the latest prices of the products, information, serving information

Structure:
Chemical Name:
Neomycin sulfate
CAS:
1405-10-3
MF:
C23H48N6O17S
Structure:
Chemical Name:
Gentamicin sulfate
CAS:
1405-41-0
MF:
C60H127N15O26S
Structure:
Chemical Name:
Tobramycin
CAS:
32986-56-4
MF:
C18H37N5O9
Structure:
Chemical Name:
Streptomycin sulfate
CAS:
3810-74-0
MF:
C21H41N7O16S
Structure:
Chemical Name:
PAROMOMYCIN SULFATE
CAS:
1263-89-4
MF:
C23H47N5O18S
Structure:
Chemical Name:
Streptomycin
CAS:
57-92-1
MF:
C21H39N7O12
Structure:
Chemical Name:
SPECTINOMYCIN DIHYDROCHLORIDE
CAS:
21736-83-4
MF:
C14H25ClN2O7
Structure:
Chemical Name:
Ribostamycin sulfate
CAS:
53797-35-6
MF:
C17H36N4O14S
Structure:
Chemical Name:
Kasugamycin hydrochloride
CAS:
19408-46-9
MF:
C14H25N3O9.ClH
Structure:
Chemical Name:
Sisomycin Sulfate
CAS:
53179-09-2
MF:
C19H39N5O11S
Structure:
Chemical Name:
KANAMYCIN SULFATE
CAS:
70560-51-9
MF:
C18H38N4O15S
Structure:
Chemical Name:
Gentamicin
CAS:
1403-66-3
MF:
C60H123N15O21
Structure:
Chemical Name:
Tobramycin sulfate
CAS:
79645-27-5
MF:
C18H39N5O13S
Structure:
Chemical Name:
Isepamicin sulfate
CAS:
67814-76-0
MF:
C22H45N5O16S
Structure:
Chemical Name:
AMIKACIN
CAS:
37517-28-5
MF:
C22H43N5O13
Structure:
Chemical Name:
Spectinomycin
CAS:
1695-77-8
MF:
C14H24N2O7
Structure:
Chemical Name:
Netilmicin sulfate
CAS:
56391-57-2
MF:
C42H92N10O34S5
Structure:
Chemical Name:
Sisomicin
CAS:
32385-11-8
MF:
C19H37N5O7
Structure:
Chemical Name:
(2R,3R,4S,5S,6R)-4-Amino-2-[(1S,2S,3R,4S,6R)-4,6-diamino-3-[(2R,3R,6S)-3-amino-6-(aminomethyl)oxan-2-yl]oxy-2-hydroxy-cyclohexyl]oxy-6-(hydroxymethyl)oxane-3,5-diol
CAS:
34493-98-6
MF:
C18H37N5O8
Structure:
Chemical Name:
Tobramycin sulfate
CAS:
49842-07-1
MF:
C18H39N5O13S
Structure:
Chemical Name:
Etimicin Sulphate
CAS:
362045-44-1
MF:
C21H43N5O7.H2O4S
Structure:
Chemical Name:
Butirosin
CAS:
12772-35-9
MF:
C21H41N5O12
Structure:
Chemical Name:
RIBOSTAMYCIN SULFATE SALT
CAS:
25546-65-0
MF:
C17H34N4O10
Structure:
Chemical Name:
NETILMICIN
CAS:
56391-56-1
MF:
C21H41N5O7
Structure:
Chemical Name:
KANAMYCIN
CAS:
59-01-8
MF:
C18H36N4O11
Chemical Name:
Framycetine sulphate BP98
Structure:
Chemical Name:
Etimicin
CAS:
59711-96-5
MF:
C21H43N5O7
Structure:
Chemical Name:
Isepamicine
CAS:
58152-03-7
MF:
C22H43N5O12
Structure:
Chemical Name:
Neomycin
CAS:
1404-04-2
MF:
C23H52N6O25S3
Chemical Name:
Viomycin sulfzte
MF:
C25H45N13O14S
Chemical Name:
Nebramycin
CAS:
11048-13-8
Structure:
Chemical Name:
Lividomycin
CAS:
36019-37-1
MF:
C29H55N5O19
Structure:
Chemical Name:
MICRONOMICIN SULFATE
CAS:
66803-19-8
MF:
C20H43N5O11S
Structure:
Chemical Name:
KANAMYCIN
CAS:
8063-07-8
MF:
C18H36N4O11
Structure:
Chemical Name:
viomycin
CAS:
32988-50-4
MF:
C25H43N13O10
Structure:
Chemical Name:
Amikacin sulfate salt
CAS:
149022-22-0
MF:
C22H45N5O17S
Structure:
Chemical Name:
FORTIMICIN
CAS:
55779-06-1
MF:
C17H35N5O6
Structure:
Chemical Name:
Bekanamycin
CAS:
4696-76-8
MF:
C18H37N5O10
Structure:
Chemical Name:
ROSAMICIN
CAS:
35834-26-5
MF:
C31H51NO9
Chemical Name:
KANAMYCIN MONOSULPHATE
MF:
C18H38N4O15S
Structure:
Chemical Name:
NEOMYCIN B
CAS:
119-04-0
MF:
C23H46N6O13
Structure:
Chemical Name:
Dibekacin sulfate
CAS:
58580-55-5
MF:
C18H37N5O11S
Structure:
Chemical Name:
DIHYDROSTREPTOMYCIN SESQUISULFATE SALT
CAS:
1425-61-2
MF:
C21H43N7O16S
Structure:
Chemical Name:
Dihydrostreptomycin
CAS:
128-46-1
MF:
C21H41N7O12